Literature DB >> 16137807

Proximal row carpectomy in advanced Kienbock's disease.

L De Smet1, Ph Robijns, I Degreef.   

Abstract

This retrospective study assessed the outcomes of 21 patients (16 male and 5 female, mean age 39 years) with advanced Kienbock's disease treated by resection of the proximal carpal row. They were clinically reviewed. The mean follow-up was 67 months, with all but two patients having had a follow-up of 2 years. No or mild pain was being experienced by 13 patients, moderate pain by 3 and severe pain by 5. Grip strength increased from 19 kg pre-operatively to 26 kg postoperatively (or 65% of the normal contralateral side). There was a slight increase of mobility. The DASH score was 22 points (range 0-78) and the Patient Rated Wrist Score (PRWS) was 30 points (range 0-84). Two patients developed Complex Regional Pain Syndrome which was ongoing at the time of review and one developed a superficial wound infection. Proximal carpal row resection arthroplasty gave satisfactory results in patients with advanced Kienbock's disease.

Entities:  

Mesh:

Year:  2005        PMID: 16137807     DOI: 10.1016/j.jhsb.2005.06.024

Source DB:  PubMed          Journal:  J Hand Surg Br        ISSN: 0266-7681


  4 in total

1.  Outcomes assessment of lunate replacement arthroplasty with intrinsic carpal ligament reconstruction in Kienböck's disease.

Authors:  Mark Henry
Journal:  Hand (N Y)       Date:  2014-09

2.  Current Trends in Treatment of Kienböck Disease: A Survey of Hand Surgeons.

Authors:  Gregory P Kolovich; Chidimma M K Kalu; Michael E Ruff
Journal:  Hand (N Y)       Date:  2016-01-13

Review 3.  [Kienböck's disease. Diagnosis and therapy].

Authors:  R E Horch; F Unglaub; A Dragu; U Kneser; A D Bach
Journal:  Chirurg       Date:  2008-05       Impact factor: 0.955

4.  The Use of MRI Modeling to Enhance Osteochondral Transfer in Segmental Kienböck's Disease.

Authors:  Lauren Barber; Matthew F Koff; Patrick Virtue; Joseph P Lipman; Robert J Hotchkiss; Hollis G Potter
Journal:  Cartilage       Date:  2012-04       Impact factor: 4.634

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.